STAT+: To lower drug prices, White House takes new aim at pharma patents
WASHINGTON — The White House is throwing its support behind a controversial authority that allows…
Author: STAT
STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion
Abbvie announced Wednesday that it will purchase Cereval Therapeutics and its pipeline of experimental neurological…
New England Journal of Medicine reckons with its racist past and complicity in slavery
The New England Journal of Medicine, the world’s oldest continually published medical journal, publicly reckoned…
.jpg)
STAT+: Stephen Hemsley, UnitedHealth Group board chair, sells nearly $113 million in stock
Stephen Hemsley, the board chair and former CEO of UnitedHealth Group, has sold nearly $113…
.jpg)
Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents
With 10 days to go, only one company has responded to a demand by the…
STAT+: Using Pap smears for earlier ovarian cancer detection shows promise in small new study
Ovarian cancer owes its often-dismal prognosis to the late stage at which it’s typically discovered….
‘Last roll of the dice’ for a near-term HIV vaccine fails
A study billed as the last chance to develop an HIV vaccine this decade has…
STAT+: Using AI, scientists create blood test that measures organ aging and predicts disease risk
In today’s mostly plague- and famine-free world, if you can avoid more modern scourges like…
STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues
In a victory for the pharmaceutical industry, a U.S. judge ruled that Minnesota must temporarily…
Morning Rounds: Couples share high blood pressure, and other health stories you should read today
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Why Cerevel Therapeutics has risen 50% in three days without changing anything
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Getting the lead out of the water supply: How one health expert crunched the numbers and prodded the EPA
It’s known that lead in the water supply has severe health effects, including brain damage…
New gene therapies confront many sickle cell patients with an impossible choice: a cure or fertility
As a teenager, Marie Tornyenu was always having to explain herself. If it wasn’t the…
Opinion: Listen: Rep. Raul Ruiz on going from the emergency room to Congress
Before he joined Congress, Rep. Raul Ruiz, a Democrat from California, worked in another chaotic…
Opinion: STAT+: A bold approach to pay for weight loss drugs for everyone who needs them
The news about anti-obesity drugs keeps getting better. In November, data presented at the American…
STAT+: Pfizer plans to depart BIO
WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources…
STAT+: CVS’s new drug payment plan won’t lower patients’ prices, experts warn
CVS Health is promising to simplify how its pharmacies get paid for drugs. But that…
STAT+: Senate panel considers Medicare policy fixes to drug shortages
WASHINGTON — Members of the Senate Finance Committee took their first steps today toward using…
STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts
NEW YORK — Will the world actually soon spend $100 billion a year on the…
STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million
Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series…
ChatGPT doesn’t know much about drugs, Hims & Hers enters weight-loss market
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
STAT Morning Rounds: The health news you need to read today
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Carmot’s chance of beating the odds in the biotech market just ended
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO
WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John…
STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research
Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis…
STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to…
Is the flu shot market a slam dunk for mRNA vaccines? Experts aren’t so sure
Here are two things that are true. The world needs more effective flu vaccines. And…
Opinion: New abortion restrictions pose a serious threat to fetal surgery
The concept of fetal surgery captures the imagination when, from time to time, it makes…
STAT+: Cancer drug shortages won’t get better under Biden’s latest plan
WASHINGTON — President Biden’s new plan to curb drug shortages by boosting domestic drug production…
STAT+: Official: FDA needs staff influx to meet gene therapy needs
WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its…
STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds
In the wake of the Covid-19 pandemic, the Food and Drug Administration inspected far fewer…
Sweeping bill to fight opioid addiction will be considered by Senate health committee
The Senate health care committee will consider a sweeping bill next week meant to combat…
Take our quiz: Can you out-science an 8th grader?
What’s a cell? An organelle? A ganglion? An acromion? Eighth grade biology is parts gross anatomy…
Supreme Court wrestles with OxyContin maker’s bankruptcy deal
WASHINGTON — The Supreme Court on Monday wrestled with a nationwide settlement with OxyContin maker…
STAT Morning Rounds: Six health news stories you need to start your day
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Novartis is building a new radioligand plant in China
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: A well-meaning FDA policy is a threat to pediatric cancer treatment
The medical community today faces a deceptively simple question: How quickly should we act when…
Opinion: Big Weed today is a whole lot like Big Tobacco in the 1950s
OK, marijuana is now legal. So where’s the public health approach? Strictly speaking, marijuana use…
STAT+: How sickle cell became the first disease treated by CRISPR
Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of…
STAT+: Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion
LONDON — The booming obesity market is attracting another player, as pharma giant Roche said…
Opinion: STAT readers on burnt-out infectious disease doctors, 12-month prescriptions, and counting disabled Americans
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
Johnson & Johnson bets heavy on AI-driven drug discovery
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too…
Life-extending epilepsy surgery performed less often in Black children, study finds
Children with drug-resistant epilepsy who are Black or insured through Medicaid may be less likely…
STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial
Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after…
STAT+: Senate Republicans throw cold water on so-called site-neutral hospital pay cuts
WASHINGTON — On its face, a minor policy to make sure Medicare pays hospitals the…